Selinexor and Venetoclax with Dexamethasone for Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies a combination of selinexor, venetoclax, and dexamethasone to treat multiple myeloma that has returned or is resistant to prior treatments. It may help shrink the myeloma and improve disease control in people with a specific myeloma genetic marker (t(11;14)).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma with the t(11;14) genetic change confirmed by a local test (FISH) on a bone marrow sample.
- Your myeloma must have come back (relapsed) and/or not responded well to treatment (refractory) after at least two prior treatment “lines,” and it must be resistant to or not suitable for IMiD, proteasome inhibitor, and anti-CD38 treatments.
- You must have measurable myeloma activity in the last 4 weeks, such as abnormal blood/urine proteins, high free light chains, enough cancer cells in marrow, or clear spots on PET/CT or MRI.
- Your blood counts and organ function must meet minimum levels (for example, neutrophils and platelets) and you must be well enough for treatment (ECOG 0–3).
- You must be able to swallow tablets and take required supportive medicines (especially anti-nausea meds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
This early-phase study tests whether selinexor combined with VRd (bortezomib, lenalidomide, and dexamethasone) can improve outcomes for people with high-risk, newly diagnosed multiple myeloma. You may be a candidate if you have certain lab/genetic signs of “high-risk” disease and haven’t had prior myeloma treatment.
Hear when a new Relapsed and Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.